• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Luminex tops Q2 estimates

August 8, 2017 By Sarah Faulkner

LuminexShares in Luminex (NSDQ:LMNX) rose today after the company beat expectations on Wall Street with its second quarter results.

The Austin, Tx.-based company posted profits of $5.5 million, or 13¢ per share, on sales of $76.5 million for the 3 months ended June 30, for bottom-line growth of -1.9% on sales growth of 19% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 26¢, ahead of consensus on The Street, where analysts were looking for sales of $75.5 million.

“I am very pleased with the company’s performance year-to-date and we remain focused on delivering double digit revenue growth and increased shareholder value. In addition, I’m happy to announce, that only a year after its acquisition, Nanosphere was accretive to the Company’s operating results in the second quarter,” president & CEO Homi Shamir said in prepared remarks. “The combination of the Aries and Verigene sample-to-answer systems coupled with our non-automated solutions has provided our customers with a technology portfolio that addresses their needs. Further, the full integration of our sales force helped drive our execution in the second quarter.”

“Looking forward, we believe that our diversified business model offers multiple, significant growth opportunities as we aggressively expand the test menu on these platforms.  With multiple clearances in the second quarter and the Aries C.Diff. assay approval in July, Luminex now has ten FDA-cleared assays that run on our automated sample-to-answer molecular systems.”

Luminex said it expects to post adjusted sales of $300 million to $310 million for the full year.

LMNX shares were trading at $20.28 apiece today in afternoon activity, up 2.1%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diagnostics, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: luminex

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS